New research analyzing a decade of hospital registry data reveals that patients who experience a brain bleed while taking multiple antiplatelet medications or stronger antiplatelet agents face a higher risk of dying in the hospital. The findings, presented at the American Stroke Association’s International Stroke Conference 2026, challenge the common practice of grouping all antiplatelet therapies together when assessing post-bleed outcomes.
The study, led by Dr. Santosh Murthy of Weill Cornell Medicine, examined data from 426,481 adults hospitalized for intracranial hemorrhage between 2011 and 2021. Among them, 109,512 were taking only aspirin, 17,009 were on dual antiplatelet therapy, and 300,558 were on no antiplatelet medications. After adjusting for demographics, comorbidities, and stroke severity, researchers found that patients on aspirin alone had no increased risk of death compared to those on no antiplatelet therapy. However, those taking stronger agents—such as clopidogrel, prasugrel, or ticagrelor—either alone or in combination with aspirin, had a significantly higher likelihood of dying in the hospital.
“Previous research has grouped all antiplatelet medications together,” Murthy said. “Our study shows that not all antiplatelet therapies are the same when it comes to outcomes after a brain bleed.” The findings underscore the need for tailored management strategies for patients on different antiplatelet regimens.
The study did not evaluate the risk of suffering a brain bleed from these medications, but rather the outcomes once a bleed occurs. Dr. Jonathan Rosand, a neurologist at Massachusetts General Hospital not involved in the study, emphasized that the benefits of dual antiplatelet therapy for preventing heart attacks and ischemic strokes often outweigh the risks. “If you’re on these medications, check with your health care professional to ensure they are still right for you,” he advised.
Current guidelines recommend discontinuing antiplatelet medications immediately after a brain bleed and do not support routine platelet transfusions unless surgery is needed. The study’s authors suggest that future research should investigate whether platelet transfusions could improve outcomes for patients on dual or stronger antiplatelet therapy.
The analysis relied on data from the American Heart Association’s Get With The Guidelines-Stroke Registry, which includes diverse hospitals across the U.S. Limitations include the lack of specific bleed characteristics, such as hematoma volume or location, which could influence prognosis. The findings are considered preliminary until published in a peer-reviewed journal.
Intracranial hemorrhage accounts for about 10% of all strokes in the U.S., according to the American Heart Association’s 2026 Heart Disease and Stroke Statistics. With stroke now the fourth leading cause of death, understanding how pre-admission medications affect outcomes is critical for improving care.
